Last reviewed · How we verify
MAD0004J08
At a glance
| Generic name | MAD0004J08 |
|---|---|
| Sponsor | Toscana Life Sciences Sviluppo s.r.l. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease. (PHASE1)
- Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAD0004J08 CI brief — competitive landscape report
- MAD0004J08 updates RSS · CI watch RSS
- Toscana Life Sciences Sviluppo s.r.l. portfolio CI